Vice President, System Clinical Strategy

M Health Fairview System

Jeff Reierson is Vice President of Clinical Strategy for the M Health Fairview System. His team leads the strategic planning process and drives strategy throughout the $5bn Fairview clinical enterprise. 

Reierson has over 15 years of global healthcare experience at Medtronic, Johnson & Johnson, and Tactile Medical driving portfolio strategy, business development (M&A), and marketing in the cardiovascular, neurovascular, and digital health space, including an expatriate role in Singapore. 

Reierson received his MBA from Duke University with a certification in Health Sector Management and his undergraduate degree from the University of Texas at Austin with a BBA in finance and a minor in Spanish.

Vice President, Strategy & Innovation

HCA Healthcare

Jessa Kelley currently leads the Technology & Advisory Practice within the Strategy & Innovation Group at HCA Healthcare where she is primarily responsible for accelerating the organization’s understanding of critical business priorities and emerging opportunities. In her current role, Kelley focuses on aligning objectives and achieving consensus through thoughtful discussion and creative collateral. 

Kelley began her career at HCA Healthcare in 2014 as the Assistant Vice President of Strategy for HCA’s Information Technology Group, where she focused on defining and aligning long-term transformative technology strategies. 

Prior to joining HCA Healthcare, Kelley spent seven years as a consultant responsible for managing several high-profile enterprise technology selections, implementations, and optimizations across the country. 

Kelley holds a Master of Business Administration with a concentration in Health Sector Management from Duke University and a Bachelor of Science from the West Chester University of Pennsylvania.

Visiting Policy Associate

Duke-Margolis

Katie Greene is a Visiting Policy Associate at the Duke-Margolis Center for Health Policy, where she focuses on issues related to the COVID-19 response, vaccine policy, opioids and substance use disorders, and other public health issues.

Prior to joining Duke-Margolis, Greene served as a Program Director for the National Governor’s Association (NGA), where she supported governors in the public health response to the COVID-19 pandemic, including issues relating to data-driven reopening strategies and public health infrastructure. In addition, Greene was the NGA’s co-lead of a joint health and public safety opioid response team for governors, governors’ staff, and states on addiction and substance use.

Previously, Greene served as Senior Policy Advisor and Associate Director of the Office of Intergovernmental and Public Liaison at the White House Office of National Drug Control Policy and Deputy Director of Federal Relations for Arizona Governor Janet Napolitano. She holds a master’s degree in public policy from the Princeton School of Public and International Affairs and a bachelor’s degree from Duke University.

Health Policy Director

U.S. Senator Richard Burr

Angela Wiles is the Health Policy Director for U.S. Senator Richard Burr (R-NC). She serves as the senior health care advisor to the Senator in his work on both the Health, Education, Labor, Pensions (HELP) Committee and the Committee
on Finance, covering health issues related to the Center for Medicare and Medicaid Services, the National Institutes of Health, the Food and Drug Administration, and other public health policies and programs.

Before joining Senator Burr’s team, Wiles worked at the American Action forum for former CBO Director Doug Holtz-Eakin and in Governor Nathan Deal’s Administration in Georgia.

President of Diagnostics and Chief Medical Officer

LabCorp

Brian Caveney, MD, JD, MPH is President of Diagnostics and Chief Medical Officer of LabCorp. Caveney has broad responsibility for medical and scientific strategy, including serving as primary medical representative for the company externally, defining global standards for medical and scientific activities across LabCorp’s Diagnostics and Drug Development businesses, and enhancing a culture of medical and scientific excellence.

Previously, Caveney was Chief Medical Officer of Blue Cross Blue Shield where he directed the development and implementation of strategies to help employers control health care costs while improving the health of their employees. Earlier in his career, Caveney served as a physician and assistant professor at Duke University Medical Center, co-directed the preventive medicine course in the Duke University School of Medicine, and also provided consulting services for several companies in the Research Triangle Park region.

He earned his MD from the West Virginia University School of Medicine, a JD from the West Virginia University College of Law and an MPH in Health Policy and Administration from the University of North Carolina at Chapel Hill. He completed his residency at Duke University Medical Center and is board-certified in preventive medicine with a specialty in occupational and environmental medicine.

Director and Robert J. Margolis, MD, Professor of Business, Medicine and Policy

Duke-Margolis

Mark McClellan, MD, PhD is the Robert J. Margolis Professor of Business, Medicine, and Health Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University.

McClellan is a physician and an economist who has informed and improved a wide range of strategies and policy reforms to advance health care, including payment reform to promote better outcomes and lower costs, methods for development and use of real-world evidence, and strategies for more effective biomedical innovation. Before coming to Duke, he served as a Senior Fellow in Economic Studies at the Brookings Institution, where he was Director of the Health Care Innovation and Value Initiatives and led the Richard Merkin Initiative on Payment Reform and Clinical Leadership.

With highly distinguished record in public service and academic research, McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These reforms include the Medicare prescription drug benefit, Medicare and Medicaid payment reforms, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and Deputy Assistant Secretary for Economic Policy at the Department of the Treasury.

McClellan is the founding chair and a current board member of the Reagan-Udall Foundation for the FDA and a member of the National Academy of Medicine (NAM), where he chairs the Leadership Council for Value and Science-Driven Health care, co-chairs the guiding committee of the Health Care Payment Learning and Action Network, and is a research associate at the National Bureau of Economic Research. He is also a Senior Advisor on the faculty of the University of Texas Dell Medical School, co-chair of the Accountable Care Learning Collaborative, and a member of the Healthtech 4 Medicaid Board of Directors. McClellan is also an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and Seer. He was previously an associate professor of economics and medicine with tenure at Stanford University, and has twice received the Kenneth Arrow Award for Outstanding Research in Health Economics.

Senior Policy Fellow

Duke-Margolis

Susan Dentzer is the Senior Policy Fellow at the Duke-Margolis Center for Health Policy at Duke University. Based in Washington, DC, she works on a range of health policy issues including health system transformation, the use of artificial intelligence and related technologies in health care, bio-pharmaceuticals policy, and improving cancer care as well as maternity and infant care. Dentzer is the editor and lead author of the book, “Health Care Without Walls: A Roadmap for Reinventing U.S. Health Care”. Dentzer previously led the Network for Excellence in Health Innovation, a nonprofit that sought to advance innovation in health care. A longtime journalist, she has been on-air analyst on health issues with the PBS NewsHour and a commentator on health policy for National Public Radio. She wrote and hosted the 2015 PBS documentary, “Reinventing American Healthcare,” focusing on the innovations pioneered by the Geisinger Health System and spread to health systems across the nation.

Dentzer was formerly Senior Policy Adviser to the Robert Wood Johnson Foundation and the Editor-in Chief of the Health Policy Journal Health Affairs. From 1998-2008 she was the on-air health correspondent for the PBS NewsHour.

Dentzer is an elected member of the National Academy of Medicine and the Council on Foreign Relations; a fellow of the National Academy of Social Insurance; and a fellow of the Hastings Center, a nonpartisan bioethics research institute. She is also on the boards of directors of the International Rescue Committee; Research!America; and the Public Health Institute. She is a member of the RAND Health Board of Advisors, the March of Dimes national public policy advisory board, and the board of the Women’s Health Activist Movement Global (WHAMglobal). She is a member of Women of Impact, and a former public member of the American Board of Medical Specialties.

Dentzer holds an honorary master’s degree from Dartmouth and an honorary doctorate from Muskingum University.

Partner

Public Opinion Strategies

Jarrett Lewis is a Partner at Public Opinion Strategies, a national political and public affairs research firm, whose clients include leading political figures, Fortune 500 companies, and major associations. The firm is also part of the bi-partisan research team that conducts the NBC News/Wall Street Journal poll. Jarrett’s work is heavily rooted in the health care industry and he has extensive experience conducting survey research and providing advisory services for large health systems and health care companies.

Jarrett was previously Executive Director of Health Policy at The Health Management Academy, a network of executive leaders from the 100-largest hospital systems across the US In that role he advised C-Suite hospital system executives on federal policy initiatives and strategy. He also created and led a business unit offering advisory services to health system executives using proprietary survey research data in areas of business development, marketing, budgeting and health policy. Additionally, he directed a quarterly health care survey of 1,500 consumers, sponsored and published by the Royal Bank of Canada (RBC). He regularly speaks to health system and health care company boards of directors and leadership teams on the topics of health policy and consumerism in health care.

Jarrett began his career at Public Opinion Strategies, providing survey research analysis to federal and state campaigns during the 2008 election cycle. He worked for Public Opinion Strategies again during the 2012 election cycle, serving as a strategist and pollster to the Romney for President Campaign from 2011-2012. In that role Jarrett provided in-depth analysis of internal survey research data to senior campaign officials, including over 300 surveys and 150 focus groups.

Jarrett is a RIVA-trained focus group moderator and has moderated or managed over 200 focus groups in his career. He has an MBA from the Fuqua School of Business at Duke University and a BA in Political Science from Clemson University, where he was a member of the men’s varsity soccer team. He lives in Alexandria, Virginia with his wife Elise and their son.

Deputy Director, Policy

Duke-Margolis

Marta E. Wosińska, PhD, is the Deputy Director, Policy at the Duke-Margolis Center for Health Policy and Consulting Professor at the Fuqua School of Business. Widely recognized as an expert on health policy, economics, and regulation, Wosińska leads the Center’s Washington, DC office. In her role, she works with Duke-Margolis leadership on developing the Center’s strategy and then executes it with support of the roughly 30-person research team based in DC.

Wosińska’s experience spans both academia as well as the executive and legislative branches of the federal government. In 2019, Wosińska served as an economic advisor to the US Senate Finance Committee, providing drug market analysis and expert guidance for the Committee’s bipartisan investigative and legislative work on drug pricing. Wosińska also served for over three years as Chief Healthcare Economist in the Office of Inspector General (OIG) at the US Department of Health and Human Services. Prior to OIG, Wosińska had a seven-year tenure at the US Food and Drug Administration (FDA) where she headed the Economics Staff at the Office of Strategic Programs in the Center for Drug Evaluation and Research and served as Senior Economic Advisor to FDA’s Deputy Commissioner for Medical Products and Tobacco, in both roles advising senior FDA leadership on a wide range of economic issues related to drugs and biologics.

Before entering public service, Wosińska was an Assistant Professor of Marketing at the Harvard Business School, where her academic research focused on prescription drug marketing. She also was a visiting Assistant Professor at the Columbia Business School, where she developed and taught Healthcare Marketing and Marketing of Pharmaceuticals and Medical Devices. Wosińska received her PhD in economics from University of California at Berkeley and a bachelor’s degree from Arizona State University.